

SAFETY DATA SHEET

1. Identification

Product Identifier: Brimonidine Tartrate Ophthalmic Solution, 0.2%

Synonyms: 5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate; Brimonidine Tartate.

National Drug Code (NDC): 17478-715-10
17478-715-11
17478-715-12

Recommended Use: Pharmaceutical.

Company: Akorn, Inc.
1925 West Field Court, Suite 300
Lake Forest, Illinois 60045

Contact Telephone: 1-800-932-5676

E mail: customer.service@akorn.com

Emergency Phone Number: CHEMTREC 1-800-424-9300 (U.S. and Canada)

2. Hazard(s) Identification

Physical Hazards: Not classifiable.

Health Hazards: Not classifiable.

Symbol(s): None.

Signal Word: None.

Hazard Statement(s): None.

Precautionary Statement(s): None.

Hazards Not Otherwise Classified: Not classifiable.

Supplementary Information: While this material is not classifiable as hazardous under the OSHA standard, this SDS contains valuable information critical to safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

3. Composition/Information on Ingredients

Chemical Name	CAS Number	Synonyms	Chemical Formula	Molecular Weight	Percentage
5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate	70359-46-5	Brimonidine Tartrate	C ₁₁ H ₁₀ BrN ₅ •C ₄ H ₆ O ₆	442.24	0.2%

*The formula also contains Benzalkonium Chloride 0.005 % as a preservative, Citric Acid, Polyvinyl Alcohol, Sodium Chloride, Sodium Citrate; Hydrochloric Acid and/or Sodium Hydroxide added to adjust pH (5.6 – 6.6), and Water for Injection.

4. First Aid Measures**Ingestion:**

If a person vomits place them in the recovery position so that vomit will not reenter the mouth and throat. Rinse mouth with water. If swallowed, seek medical advice immediately and show the container or label. Treat symptomatically and supportively. Ensure that medical personnel are aware of the material(s) involved and take precautions to protect themselves.

Eye Contact:

Remove from source of exposure. Flush with copious amounts of water for at least 15 minutes. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect themselves.

Skin Contact:

Remove from source of exposure. Remove and isolate contaminated clothing and shoes. Flush with copious amounts of water for at least 20 minutes. Use soap. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect themselves.

Inhalation:

Remove from source of exposure. Move individual(s) to fresh air. Give artificial respiration if individual(s) are not breathing and call emergency medical service. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. Ensure that medical personnel are aware of the material(s) involved and are aware of precautions to protect themselves.

Protection of First-Aiders:

Use personal protective equipment (see section 8).

Signs and Symptoms:

Oral dryness; ocular hyperemia; burning and stinging of eyes; headache; blurring of vision; foreign body in eyes sensation; fatigue/drowsiness; conjunctival follicles; ocular allergic reactions; ocular irritation; photophobia; ocular dryness; tearing; upper respiratory symptoms; dizziness; gastrointestinal symptoms; weakness; muscular pain; insomnia; depression; hypertension; anxiety; palpitations/arrhythmias; nasal dryness; syncope; bradycardia; hypotension; iritis; miosis; skin reactions (including erythema, eyelid purities, rash, and vasodilation); and tachycardia.

Medical Conditions Aggravated by Exposure:

Cardiovascular disease; hepatic or renal impairment; depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans; hypersensitivity to brimonidine tartrate or any component of this medication.

SDS: Brimonidine Tartrate Ophthalmic Solution, 0.2%

Notes to Physician: Treat supportively and symptomatically.

5. Firefighting Measures

Suitable Extinguishing Media: Use extinguishing media for type of surrounding fire.

Unsuitable Extinguishing Media: Not determined.

Specific Hazards Arising from the Chemical:

Hazardous Combustion Products: These products include carbon oxides nitrogen oxides, and hydrogen bromide.

Other Specific Hazards: Closed containers may explode from the heat of fire.

**Special Protective Equipment/
Precautions for Firefighters:** Wear self-contained breathing apparatus and full and protective gear.

6. Accidental Release Measures

Personal Precautions: Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate personal protective equipment and clothing.

Personal Protective Equipment: For personal protection see section 8.

Methods for Cleaning Up: Dike ahead of liquid spills for later disposal. Absorb with inert material. Recover product and place in an appropriate container for disposal in accordance with local, state and federal regulations.

Environmental Precautions: Contain material and prevent release to basements, confined spaces, waterways or soil.

Reference to Other Sections: Refer to Sections 8, 12 and 13 for further information.

7. Handling and Storage

Precautions for Safe Handling: Handle in accordance with product label and/or product insert information. Handle in accordance with good industrial hygiene and safety practices.

**Conditions for Safe Storage,
Including Any Incompatibilities:** Store according to label and/or product insert information. Store away from acids, bases and oxidizing agents.

Specific End Use: Pharmaceuticals.

8. Exposure Controls/Personal Protection

Occupational Exposure Guidelines:

Common or Chemical Name	Employee Exposure Limits
Brimonidine Tartrate	OEL*: 12.5 µg/m ³ , 8 Hour TWA

* An Occupational Exposure Levels (OEL) has been established by private industry.

Engineering Controls:	Engineering controls should be used as the primary means to control exposures.
Respiratory Protection:	Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134).
Eyes Protection:	Safety glasses with side shields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.
Hand Protection:	Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic non-latex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.
Skin Protection:	Protective laboratory coat, apron, or disposable garment.

9. Physical and Chemical Properties

Physical State/Color:	Liquid/Greenish-Yellow.
Odor:	No data available.
Odor Threshold:	No data available.
pH:	5.6 – 6.6.
Melting Point:	No data available.
Freezing Point:	No data available.
Boiling Point:	No data available.
Flash Point:	No data available.
Evaporation Rate:	No data available.
Flammability (solid, gas):	No data available.
Flammability Limit - Lower:	No data available.
Flammability Limit - Upper:	No data available.
Vapor Pressure:	No data available.
Vapor Density:	No data available.
Relative Density:	No data available.
Solubility(ies):	Miscible in water.
Partition Coefficient (n-octanol/water):	No data available.

Auto-Ignition Temperature: No data available.
 Decomposition Temperature: No data available.
 Viscosity: No data available.

10. Stability and Reactivity

Reactivity: No data available.

Chemical Stability: Stable under recommended storage conditions.

Possibility of Hazardous Reactions: No data available.

Conditions to Avoid (e.g., static discharge, shock, or vibration): No data available.

Incompatible Materials: Strong oxidizing agents, acids and bases.

Hazardous Decomposition Products: No data available.

11. Toxicological Information

Information on the Likely Routes of Exposure:

Inhalation: May be harmful if inhaled. May cause respiratory tract irritation.

Ingestion: May be harmful if swallowed.

Skin Contact: May be harmful if absorbed through the skin. May cause irritation.

Eye Contact: May cause eye irritation.

Symptoms Related to the Physical, Chemical and Toxicological Characteristics: See Section 4. To the best of our knowledge, the chemical, physical and toxicological properties have not been thoroughly investigated.

Delayed and Immediate Effects of Exposure: No data available.

Acute Toxicity:

Compound	Species	Route	Test Type	Dose
Brimonidine Tartrate	Rat	Oral	LD ₅₀	100 mg/kg
Brimonidine Tartrate	Mouse	Oral	LD ₅₀	50 mg/kg

Acute Toxicity – Dermal: No data available.

Acute Toxicity – Inhalation: No data available.

Corrosivity: No data available.

Dermal Irritation: No data available.

Eye Irritation: No data available.

Sensitization: No data available.

Toxicokinetics/Metabolism: No data available.

SDS: Brimonidine Tartrate Ophthalmic Solution, 0.2%

Target Organ Effects:	No data available.
Reproductive Effects:	No data available.
Carcinogenicity:	No data available.

National Toxicology Program (NTP):	Not considered to be a carcinogen.
------------------------------------	------------------------------------

International Agency for Research on Cancer (IARC):	Not considered to be a carcinogen.
---	------------------------------------

Occupational Safety and Health Administration (OSHA):	Not considered to be a carcinogen.
---	------------------------------------

Mutagenicity:	No data available.
Aspiration Hazard:	No data available.

12. Ecological Information

Ecotoxicity

Aquatic:	No data available.
Terrestrial:	No data available.
Persistence and Degradability:	No data available.
Bioaccumulative Potential:	No data available.
Mobility in Soil:	No data available.
Mobility in Environment:	No data available.
Other Adverse Effects:	No data available.

13. Disposal Considerations

Dispose of all waste in accordance with Federal, State and Local regulations.

14. Transport Information

UN Number:	Not applicable.
UN Proper Shipping Name:	Not applicable.
Transport Hazard Class(es):	Not applicable.
Packing Group:	Not applicable.

Department of Transportation:	Not regulated as a hazardous material.
--------------------------------------	--

International Air Transport Association (IATA):	Not regulated as a dangerous good.
--	------------------------------------

International Maritime Dangerous Good (IMDG):	Not regulated as a dangerous good.
--	------------------------------------

15. Regulatory Information

US Federal Regulations:

Toxic Substance Control Act (TSCA):	This product is a drug regulated by the Food and Drug Administration (FDA), and is not regulated by TSCA.
--	---

CERCLA Hazardous Substance and Reportable Quantity:	Not listed.
--	-------------



SDS: Brimonidine Tartrate Ophthalmic Solution, 0.2%

SARA 313: Not listed.
SARA 302: Not listed.

State Regulations

Massachusetts: Not listed.
New Jersey: Brimonidine Tartrate.
Pennsylvania: Brimonidine Tartrate.
California Proposition 65: Not listed.

16. Other Information

Not made with natural rubber latex.

NFPA Rating:		HMIS Classification:	
Health:	2	Health:	2
Flammability:	0	Flammability:	0
Reactivity:	0	Physical Hazard:	0

Revision Date: 06/18/2015

Revision Number: 2

Disclaimer: This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this SDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user's responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this SDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product.